Pharmafile Logo

Focus on Rare Diseases

As pharma becomes more focused on rare disease therapies, Lucid Group recognises that medical education agencies need to respond.

- PMLiVE
The US government passed the Orphan Drug Act in 1983, and it was subsequently adopted in other key markets, most notably in Japan in 1993 and the European Union in 2000. Growth in this sector has remained around 12% annually, which is more than double that experienced in the general drug market. According to the 2015 Orphan Drug Report, worldwide orphan drug sales will reach $178 billion by 2020 and will account for 20% of all prescription drug sales by 2020*. 

The trend is clear: as science and technology advances, and the rise of the internet and social media enables patients and researchers to gather and share information more effectively, we are seeing treatments for rare diseases that only a few years ago would have led to an early death. 

Alison Cantle, Rare Disease Business Unit Director at Lucid Group, explains what this means for medical education agencies: “As pharmaceutical organisations focus on personalised medicine, the need for rare disease expertise in their medical education agencies is paramount. Lucid recognised this and structured its business last year to create a unit specialising in rare diseases.” 

Within this unit, Lucid Group had recruited a team of highly skilled medical writers who combine a deep and robust understanding of the science with experience of working with rare disease specialists across the globe.

“Our rare disease team understands the cornerstones of rare disease education and what makes it different from other therapy areas. It is essential to build networks and enable best practice sharing,” Alison explains. “And in rare disease, more so than in any other therapy area, the choice of agency is crucial, as often it is your agency who represents your organisation at the communication level – so its voice has to be your voice.” 

Patients who have a rare disease face difficulty in every step of medical care, including diagnosis, treatment and preserving quality of life. Sometimes, patients go years without receiving the correct diagnosis for their condition. So raising awareness, improving time to diagnosis, getting patients to the right care, and improving family and emotional support and reimbursement are just some of the areas where medical education agencies can support pharma clients. 

Lucid’s Rare Disease Business Unit currently works with clients in Fabry disease, Pompe disease, Gaucher disease, cystinosis and PKU.  For further information about working with Lucid’s Rare Disease Business Unit, please call Alison on 01494 552078 or email alison@lucid-uk.com. 

* EvaluatePharma Orphan Drug Report 2015

This content was provided by Lucid Group Communications Limited

Company Details

 Latest Content from  Lucid Group Communications Limited 

A summer meeting full of magical moments

In their day-to-day, everybody at Lucid Group strives to develop outstanding medical education programmes to improve patient outcomes. Over the summer, however, they like to take some time to turn...

Sir Henry presents Queen’s Award for Enterprise to Lucid Group

On 13 July, Lord Lieutenant Sir Henry presented Lucid Group with the Queen’s Award for Enterprise in International Trade. This award recognises UK-based businesses that have achieved outstanding growth overseas...

Lucid Group’s winning formula is recognised at Communiqué 2017

Lucid Group’s commitment to improving patient outcomes across the globe was recognised at the 2017 Communiqué Awards in London last night. The agency won the awards for Excellence in Communications...

Lucid Partners grows its medical writing team

The past year has been the most successful for Lucid Group yet. They have celebrated their 10th year of business, launched their new Strategic Consultancy, won a Queen’s Award for...

Using insights to effect behaviour change

The days when medical communication simply aimed to raise awareness of clinical challenges are well and truly over. In recent years, we have seen a clear shift towards changing physicians’...

All five of Lucid’s entries reach the shortlist for Communiqué 2017

Lucid Group is thrilled to learn that all its entries for the 2017 Communiqué Awards have been shortlisted as finalists! The categories include: Communications Consultancy of the Year Lucid Group   Excellence in Communications via...

Your career starts here

When working in medical communications, one of the most common questions we get asked is “What is it that you actually do?” Many students and graduates are unaware of medical...

Are you suffering from templatitis?

At times, it feels like procedures are designed to frustrate, and templates often hinder rather than help. Especially in strategic planning, where a certain degree of creativity and innovation is...

It’s time to shine for Lucid’s rare disease team

No team members were getting their hands dirty today! Instead, they were treated to car valets and manicures as a thank you for all their hard work delivering a number...

Focus on Rare Diseases

As pharma becomes more focused on rare disease therapies, Lucid Group recognises that medical education agencies need to respond.